Invitation to presentation of Bactiguard’s interim report on July 14, 2022
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday July 14, 2022 at 8:00 CET.
In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on July 14. CEO Anders Göransson and CFO Carin Jakobson will present the interim report and answer questions. The report and a presentation for the audiocast will be available at Bactiguard’s website www.bactiguard.com.
To participate in the webcast, please use this link:
https://www.bactiguard.com/Q2-2022
To participate only by conference call, please dial:
SE: +46850558358, UK: +443333009274, US: +16467224904
Questions can be asked either in writing via the audiocast or orally if you attend the conference call.
For further information, please contact:
Carin Jakobson, CFO, mobile: +46 70 965 16 65
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard: www.bactiguard.com
